Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults
RBL
Rituximab-Containing Immunochemotherapy for Burkitt's Lymphoma (BL) and High-Grade B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and BL
1 other identifier
observational
43
1 country
1
Brief Summary
This retrospective study is aimed at evaluating the safety and efficacy of rituximab-containing immunochemotherapy in adult patients with Burkitt's lymphoma (BL) or high-grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2013
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2013
CompletedFirst Submitted
Initial submission to the registry
March 8, 2013
CompletedFirst Posted
Study publicly available on registry
March 13, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2014
CompletedFebruary 24, 2017
February 1, 2017
1.1 years
March 8, 2013
February 22, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Event-free survival
Event-free survival is measured from the time from treatment initiation to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death)
one year
Secondary Outcomes (3)
complete response rate
1-year
overall survival
1-year
Grade 4 hematologic toxicities
one year
Study Arms (1)
Patients with Burkitt's Lymphoma
should be diagnosed pathologically by WHO 2008 criteria
Interventions
Eligibility Criteria
patients who were treated with Burkitt's or Burkitt-like high-grade B-cell lymphoma in Republic of Korea
You may qualify if:
- pathologically confirmed Burkitt's lymphoma (BL) or High grade B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and BL (BL-U) by WHO 2008 criteria
- age \>20 yrs
- received rituximab+chemotherapy as first-line treatment
- with measurable or evaluable lesion
You may not qualify if:
- \. patients with BL or BL-U previously treated with rituximab
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Gachon University Gil Medical Center
Incheon, 405-760, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Suk Jin Kim, MD, PhD
Samsung Medical Center, Seoul, Korea
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor, Department of Internal Medicine
Study Record Dates
First Submitted
March 8, 2013
First Posted
March 13, 2013
Study Start
February 1, 2013
Primary Completion
March 1, 2014
Study Completion
March 1, 2014
Last Updated
February 24, 2017
Record last verified: 2017-02